{"ABBV": {"Ticker": "ABBV", "Company": "AbbVie", "Sector": "Health Care", "Updated": "2022-05-06", "Rating": [{"Date": "2022-05-06", "Rating": "Downgrade", "Organization": "Daiwa Securities", "Rating_Change": "Outperform to Neutral", "Target_Change": "$150"}, {"Date": "2022-04-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Overweight", "Target_Change": "$192"}, {"Date": "2022-02-28", "Rating": "Downgrade", "Organization": "UBS", "Rating_Change": "Buy to Neutral", "Target_Change": "$129 to $147"}], "Score": -0.33, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 3, "Period": "180 days", "Letter_Rating": "C", "Analists": ["Daiwa Securities", "Morgan Stanley", "UBS"], "Price_Target": 163.0}, "BLL": {"Ticker": "BLL", "Company": "Ball Corp", "Sector": "Materials", "Updated": "2022-05-06", "Rating": [{"Date": "2022-05-06", "Rating": "Downgrade", "Organization": "RBC Capital Mkts", "Rating_Change": "Outperform to Sector Perform", "Target_Change": "$100 to $81"}, {"Date": "2022-03-07", "Rating": "Upgrade", "Organization": "BofA Securities", "Rating_Change": "Neutral to Buy", "Target_Change": "$103 to $108"}, {"Date": "2022-03-03", "Rating": "Upgrade", "Organization": "BMO Capital Markets", "Rating_Change": "Market Perform to Outperform", "Target_Change": "$87 to $105"}], "Score": 0.67, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 3, "Period": "180 days", "Letter_Rating": "B", "Analists": ["BofA Securities", "BMO Capital Markets", "RBC Capital Mkts"], "Price_Target": 98.0}, "CTVA": {"Ticker": "CTVA", "Company": "Corteva", "Sector": "Materials", "Updated": "2022-05-06", "Rating": [{"Date": "2022-05-06", "Rating": "Downgrade", "Organization": "JP Morgan", "Rating_Change": "Overweight to Neutral", "Target_Change": "$58"}, {"Date": "2022-04-14", "Rating": "Upgrade", "Organization": "Loop Capital", "Rating_Change": "Hold to Buy", "Target_Change": "$69"}, {"Date": "2022-04-14", "Rating": "Downgrade", "Organization": "Vertical Research", "Rating_Change": "Buy to Hold", "Target_Change": "$58"}], "Score": -0.67, "Cumulative_Rating": "Underperform", "Number_of_Analysts": 3, "Period": "180 days", "Letter_Rating": "D", "Analists": ["Loop Capital", "Vertical Research", "JP Morgan"], "Price_Target": 61.67}, "HBI": {"Ticker": "HBI", "Company": "Hanesbrands", "Sector": "Consumer Discretionary", "Updated": "2022-05-06", "Rating": [{"Date": "2022-05-06", "Rating": "Downgrade", "Organization": "Stifel", "Rating_Change": "Buy to Hold", "Target_Change": "$26 to $13"}], "Score": -1.0, "Cumulative_Rating": "Underperform", "Number_of_Analysts": 1, "Period": "180 days", "Letter_Rating": "D", "Analists": ["Stifel"], "Price_Target": 13.0}, "UAL": {"Ticker": "UAL", "Company": "United Airlines", "Sector": "Industrials", "Updated": "2022-05-06", "Rating": [{"Date": "2022-05-06", "Rating": "Upgrade", "Organization": "Wolfe Research", "Rating_Change": "Underperform to Peer Perform", "Target_Change": ""}, {"Date": "2022-04-22", "Rating": "Upgrade", "Organization": "JP Morgan", "Rating_Change": "Underweight to Overweight", "Target_Change": "$60 to $76"}, {"Date": "2022-04-22", "Rating": "Upgrade", "Organization": "Argus", "Rating_Change": "Hold to Buy", "Target_Change": "$59"}, {"Date": "2022-04-18", "Rating": "Downgrade", "Organization": "UBS", "Rating_Change": "Buy to Neutral", "Target_Change": "$51"}, {"Date": "2022-03-18", "Rating": "Upgrade", "Organization": "Exane BNP Paribas", "Rating_Change": "Underperform to Neutral", "Target_Change": "$38"}, {"Date": "2022-02-15", "Rating": "Resumed", "Organization": "Wolfe Research", "Rating_Change": "Underperform", "Target_Change": ""}], "Score": 0.67, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 6, "Period": "180 days", "Letter_Rating": "B", "Analists": ["Argus", "Exane BNP Paribas", "UBS", "JP Morgan", "Wolfe Research"], "Price_Target": 35.33}, "VRTX": {"Ticker": "VRTX", "Company": "Vertex Pharmaceuticals", "Sector": "Health Care", "Updated": "2022-05-06", "Rating": [{"Date": "2022-05-06", "Rating": "Downgrade", "Organization": "Robert W. Baird", "Rating_Change": "Outperform to Neutral", "Target_Change": "$250"}, {"Date": "2022-05-03", "Rating": "Upgrade", "Organization": "Morgan Stanley", "Rating_Change": "Underweight to Equal-Weight", "Target_Change": "$250"}], "Score": -0.5, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 2, "Period": "180 days", "Letter_Rating": "C", "Analists": ["Robert W. Baird", "Morgan Stanley"], "Price_Target": 250.0}}